<DOC>
	<DOCNO>NCT02438709</DOCNO>
	<brief_summary>The purpose study determine whether COX-2 inhibitor effective treatment primary hypertrophic osteoarthropathy</brief_summary>
	<brief_title>Effect Observation Study COX-2 Inhibitor Treat Primary Hypertrophic Osteoarthropathy</brief_title>
	<detailed_description>Patients primary hypertrophic osteoarthropathy ( PHO ) diagnose base clinical manifestation symptom . PHO patient treat COX-2 inhibitor signing informed consent . The extend alleviation , change marker prostaglandin E metabolic pathway adverse event different time point record identify efficacy safety .</detailed_description>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Osteoarthropathy , Primary Hypertrophic</mesh_term>
	<mesh_term>Osteoarthropathy , Secondary Hypertrophic</mesh_term>
	<mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
	<criteria>diagnose primary hypertrophic osteoarthropathy clinically 16 year old medication intake informed consent sign 16 year old active gastric ulcer inflammatory bowel disease New York Heart Association classification（NYHA） II IV liver renal failure allergic nonsteroid antiinflammatory drug willing participate</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>